Spots Global Cancer Trial Database for erbb2
Every month we try and update this database with for erbb2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | NCT00486954 | Neoplasms, Gast... | Lapatinib Paclitaxel | 20 Years - | GlaxoSmithKline | |
| Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | NCT03043313 | Metastatic Colo... | Trastuzumab Tucatinib | 18 Years - | Seagen Inc. | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | NCT03043313 | Metastatic Colo... | Trastuzumab Tucatinib | 18 Years - | Seagen Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | NCT04460456 | HER2 Positive S... | SBT6050 pembrolizumab Cemiplimab | 18 Years - | Silverback Therapeutics | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | NCT01137994 | Neoplasms, Brea... | Lapatinib Trastuzumab Docetaxel Paclitaxel Vinorelbine | 18 Years - | GlaxoSmithKline | |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | NCT00089999 | Neoplasms, Brea... | Lapatinib | 18 Years - | GlaxoSmithKline | |
| Study of DF1001 in Patients With Advanced Solid Tumors | NCT04143711 | Solid Tumor, Ad... | DF1001 Nivolumab Nab paclitaxel Sacituzumab Gov... | 18 Years - | Dragonfly Therapeutics | |
| GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | NCT00251433 | Neoplasms, Brea... | lapatinib, doce... | 18 Years - | Novartis | |
| Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis | NCT02560311 | ERBB2 Breast Cancer Metastatic Neop... | observation | - | University of Zurich | |
| GW572016 In Patients With Advanced Or Metastatic Breast Cancer | NCT00462956 | Neoplasms, Brea... | Tykerb | 20 Years - 40 Years | GlaxoSmithKline | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | NCT02213042 | Neoplasms, Brea... | Lapatinib Trastuzumab Aromatase Inhib... | 18 Years - | Novartis | |
| ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | NCT00272987 | Neoplasms, Brea... | lapatinib paclitaxel trastuzumab | 18 Years - | Novartis | |
| Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | NCT00486954 | Neoplasms, Gast... | Lapatinib Paclitaxel | 20 Years - | GlaxoSmithKline | |
| Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis | |
| GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer | NCT00320411 | Neoplasms, Brea... | lapatinib | 20 Years - 74 Years | GlaxoSmithKline | |
| GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer | NCT00371488 | Neoplasms, Brea... | GW572016 oral t... | 20 Years - 74 Years | GlaxoSmithKline | |
| Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | NCT00709618 | Neoplasms, Brea... | Lapatinib, Vino... | 18 Years - | GlaxoSmithKline | |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | NCT00089999 | Neoplasms, Brea... | Lapatinib | 18 Years - | GlaxoSmithKline | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Brain Metastases In ErbB2-Positive Breast Cancer | NCT00437073 | Neoplasms, Brea... | capecitabine topotecan lapatinib | 18 Years - | GlaxoSmithKline | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | NCT01953926 | Solid Tumors Ha... | Neratinib Fulvestrant Trastuzumab Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
